MOTS-C vs Humanin is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
MOTS-C and Humanin are both popular research peptides that work through different mechanisms. MOTS-C is a Mitochondrial-derived peptide, metabolic regulator focused on improved insulin sensitivity, while Humanin is a Mitochondrial-derived peptide, cytoprotective factor targeting neuroprotection.
What Are MOTS-C and Humanin?
MOTS-C (Mitochondrial ORF of the 12S rRNA Type-C) is a Mitochondrial-derived peptide, metabolic regulator. Encoded by the 12S rRNA region of the mitochondrial genome; naturally produced in response to stress, exercise, and aging. It is researched for improved insulin sensitivity, glucose metabolism, fat loss, lean muscle preservation, exercise capacity enhancement, anti-aging, metabolic flexibility.
Humanin (Humanin mitochondrial-derived peptide) is a Mitochondrial-derived peptide, cytoprotective factor. Endogenous 24-amino acid peptide encoded within mitochondrial DNA, released under stress conditions as a survival signal. It is researched for neuroprotection, Alzheimer's disease mitigation, cognitive preservation, anti-aging, metabolic health, mitochondrial restoration.
While both are popular research peptides, they work through fundamentally different mechanisms and serve different primary purposes.
How Do MOTS-C and Humanin Work Differently?
MOTS-C mechanism: Translocates to the nucleus where it regulates gene expression through the Folate-AICAR-AMPK pathway. Activates antioxidant response elements (ARE) and interacts with NRF2 transcription factor to enhance cellular stress resistance. Improves insulin sensitivity and glucose metabolism through AMPK pathway activation, essentially mimicking exercise at the molecular level.
Humanin mechanism: Stabilizes mitochondrial function and prevents mitochondrial dysfunction-induced neuronal death. Activates survival signaling through IGF-1R and MAPK pathways. Reduces oxidative stress and exerts anti-inflammatory effects by reducing pro-inflammatory cytokine production. Specifically protects against Aβ42-induced neuronal damage in Alzheimer's models.
These distinct mechanisms are why the two peptides are often used for different research goals — or combined to target multiple pathways.
How Do the Dosing Protocols Compare?
MOTS-C: 5-10 mg per week administered 2-3 times weekly via subcutaneous injection. Half-life: not established in humans. Cycle: 8-12 weeks with 8-12 week breaks.
Humanin: 2.5 mg/kg (animal studies); human dosing not established administered twice daily in animal protocols via subcutaneous injection (proposed for humans). Half-life: ~30 minutes in mice; >4 hours in rats. Cycle: human protocol undefined; chronic dosing in animal models.
Use our peptide calculator for reconstitution math for either compound.
How Do the Benefits Compare?
MOTS-C benefits: improved insulin sensitivity, glucose metabolism, fat loss, lean muscle preservation, exercise capacity enhancement, anti-aging, metabolic flexibility.
Humanin benefits: neuroprotection, Alzheimer's disease mitigation, cognitive preservation, anti-aging, metabolic health, mitochondrial restoration.
The overlap in benefits determines whether these peptides compete for the same use case or complement each other in a stack.
How Do the Side Effects Compare?
MOTS-C: Generally well-tolerated. Mild injection site reactions and transient digestive disturbances at higher doses. CB4211 analog showed good tolerability in a 4-week human trial.
Humanin: No significant side effects in preclinical studies. Human safety data completely absent. Potential for antibody formation with chronic use.
Can You Stack MOTS-C and Humanin Together?
Many researchers combine MOTS-C and Humanin in stacking protocols. The different mechanisms mean they can potentially provide complementary effects without competing for the same receptors.
Pairs with SS-31 (another mitochondrial-targeting peptide) for enhanced mitochondrial biogenesis, and with 5-Amino-1MQ for comprehensive metabolic optimization. See our stacking guide for general principles.
Which Is Better: MOTS-C or Humanin?
There is no universal answer. MOTS-C may be preferable for researchers focused on improved insulin sensitivity, while Humanin is stronger for neuroprotection.
For the most comprehensive results, many researchers combine both. Review each compound's individual guide for detailed protocols: MOTS-C | Humanin.
Complete Guide
MOTS-c: The Metabolic Mitochondrial Peptide
Research-Grade Sourcing
If you're going to research MOTS-C vs Humanin, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is MOTS-C vs Humanin?
MOTS-C vs Humanin (MOTS-C vs Humanin) is a research peptide. Synthetic peptide. It is researched for various applications.
What is the recommended MOTS-C vs Humanin dosage?
Common dosages: varies administered per protocol via subcutaneous injection. Cycle length: 4-12 weeks. Half-life: varies. Use our peptide calculator for exact reconstitution math.
What are the side effects of MOTS-C vs Humanin?
Limited safety data available. Potential injection site reactions and individual sensitivity. No serious adverse events documented in available literature.
Is MOTS-C vs Humanin safe?
MOTS-C vs Humanin has shown a preliminary safety profile in research. Not FDA-approved. Available as a research chemical in most jurisdictions. All research should follow appropriate safety protocols.